All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

CJC-1295 NO DAC peptide

CJC-1295 NO DAC peptide is a synthetic peptide studied for its ability to stimulate the natural release of growth hormone (GH). It belongs to a class of compounds known as growth hormone–releasing hormone (GHRH) analogues, which activate hormonal pathways controlling growth hormone secretion.

CJC-1295 without DAC is a modified version of the biologically active fragment of Growth hormone–releasing hormone.

The “NO DAC” designation refers to the absence of a Drug Affinity Complex (DAC) modification. Without this modification, the peptide has a shorter half-life, which results in a pattern of activity closer to the body’s natural pulsatile growth hormone signaling.

Because of these characteristics, CJC-1295 (NO DAC) has been investigated in research related to endocrine regulation and growth hormone physiology.

How CJC-1295 NO DAC peptide works

CJC-1295 NO DAC peptide stimulates GHRH receptors in the pituitary gland, which triggers the release of growth hormone through the body’s natural regulatory pathways. Research suggests that the peptide may:

  • stimulate pulsatile secretion of growth hormone

  • increase circulating insulin-like growth factor-1 (IGF-1) through activation of the GH axis

  • influence metabolic processes related to growth hormone signaling

Unlike the long-acting form of CJC-1295 that includes the DAC modification, the NO DAC version:

  • has a much shorter duration of action

  • produces a more transient stimulation of GH release

  • more closely resembles the behavior of natural GHRH signaling

Because of these properties, it has been used in experimental research studying hormonal regulation and endocrine physiology.

Clinical trials and evidence

Research involving GHRH analogues such as CJC-1295 has focused on their effects on growth hormone secretion and endocrine signaling. Experimental and early clinical studies have examined:

  • stimulation of growth hormone release in humans

  • changes in IGF-1 levels following GHRH analogue administration

  • interactions between GHRH analogues and ghrelin receptor agonists

Some studies have shown that GHRH analogues can significantly increase circulating growth hormone levels under controlled conditions.

However, CJC-1295 (NO DAC) itself has not progressed to widespread pharmaceutical approval, and most available data come from laboratory research and early-stage clinical investigations.

Possible side effects of CJC-1295 NO DAC peptide:

Because CJC-1295 (NO DAC) affects the growth hormone axis, potential side effects may be related to changes in hormonal signaling. Reported or possible side effects may include:

  • headache

  • flushing

  • mild water retention

  • fatigue

  • injection site reactions

As with other investigational peptides affecting endocrine pathways, the long-term safety profile has not been fully established.

CJC-1295 (NO DAC) is considered an experimental peptide studied primarily in endocrine and metabolic research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

CJC-1295 NO DAC
Action: GH pulse stimulation | Category: GHRH analog
Experimental dosage: 100 mcg | Frequency: every day | Timing: evening | Cycle on: 6 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 6–8 weeks
Effectiveness: ■■■▢▢ | Safety: ■■■▢▢

Related peptides

Peptides from the same functional group:AOD9604, CJC-1295 with DAC, GHRP-2, GHRP-6, Hexarelin, Ipamorelin

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged